Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength

Morgan Stanley has upgraded Amicus Therapeutics (FOLD) to Overweight with a $12 price target, citing the company's strong intellectual property position, anticipated long-term patient transition to PomOp, and robust financial health, including a 90.6% gross profit margin. Despite a Q1 2025 revenue miss attributed to specific timing and UK rebate rates, Amicus achieved 15% year-over-year total revenue growth and reiterated its goal for H2 2025 GAAP profitability. This positive re-rating is further supported by recent strategic developments, including the licensing of U.S. commercial rights for DMX-200 and securing approval for its Pompe disease treatment in Japan, expanding its market reach.

Analysis

Morgan Stanley has upgraded Amicus Therapeutics (FOLD) to Overweight with a $12.00 price target, signaling confidence despite a mixed first-quarter 2025 report. The upgrade is underpinned by the company's strong intellectual property portfolio ahead of a key judgment, expected long-term patient migration to its PomOp therapy, and the recent licensing of U.S. rights for DMX-200. While Q1 earnings per share of $0.03 surpassed the expected loss of $0.02, revenue of $125.25 million missed the $136.65 million consensus. This shortfall was attributed to specific factors, including order timing and a higher-than-anticipated UK rebate rate of 22%. Notwithstanding this miss, the company's underlying fundamentals appear robust, demonstrated by 15% year-over-year total revenue growth, a 92% surge in Pombiliti + Opfolda sales, and a strong 28.25% revenue increase over the last twelve months. Amicus has reiterated its goal to achieve GAAP profitability in the second half of 2025 and issued full-year revenue growth guidance of 15-22%. Further positive developments include regulatory approval in Japan for its Pompe disease treatment, expanding its international market access.

Key Decisions for Investors

• Given the positive analyst re-rating, strong underlying growth, and key strategic developments like the Japan approval and DMX-200 licensing, investors may consider the stock favorably, viewing the Q1 revenue miss as a temporary issue.
• It is crucial to monitor the sales trajectory of Pombiliti + Opfolda and the company's execution towards its stated goal of achieving GAAP profitability in the second half of 2025, as these are key catalysts for the thesis.
• Investors should note the near-term execution risk highlighted by the Q1 revenue miss and Morgan Stanley's slightly below-consensus Q2 sales estimates, which could create potential stock price volatility in the coming quarters.